A Phase 3 interventional study of Insulin glargine,300 U/mL and Insulin glargine (100 units /mL) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 107 sites in 24 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 8th largest by enrollment, is one of 2 that started in 2016, is one of 18 in phase 3, and was the 49th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 463 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 11th largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 3, and was the 41st registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes mellitus.
.
Secondary Objectives:
To compare HOE901-U300 and Lantus in terms of:
The study duration per participant was approximately 58 weeks that consisted of a 2 week screening period, a main 6-month comparative efficacy and safety treatment period, a 6-month comparative safety extension period, and a 4-week post treatment follow up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HOE901-U300 (Insulin glargine 300 Units/milliliter \[U/mL\]) Subcutaneous(SC) injection once daily for 12 months.
Drug: Insulin glargine,300 U/mL · Drug: Background therapy
Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
Drug: Insulin glargine (100 units /mL) · Drug: Background therapy
Drug page: Insulin Glargine
Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
Also known as: Toujeo ®
Drug page: Insulin Glargine
Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
Fast-acting mealtime insulin analogs
Change From Baseline in HbA1c to Month 6
Change in HbA1c was calculated by subtracting baseline value from Month 6 value. Adjusted least-square (LS) means and standard errors (SE) were obtained using analysis of covariance (ANCOVA) after multiple imputations of missing data using post-baseline HbA1c data available on the main 6-month randomized period.
Time frame: Baseline to Month 6
Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6
Change in FPG was calculated by subtracting baseline value from Month 6 value. Adjusted LS means and SE were obtained using ANCOVA after multiple imputation to address missing data in the main 6 month randomized period.
Time frame: Baseline to Month 6
Percentage of Participants With HbA1c Values of <7.5% at Month 6
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
Time frame: Month 6
Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
Time frame: upto Month 6
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6
Participants without any available FPG assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
Time frame: Month 6
Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
Time frame: upto Month 6
Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6
8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%), randomization strata of age at screening (\<12 years, \>=12 years) and the baseline 24-hour average 8-point profile SMPG.
Time frame: Baseline to Month 6
Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6
8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Variability was assessed by the coefficient of variation (standard deviation divided by mean) calculated over the 8-point SMPG. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
Time frame: Baseline, Month 6
Change From Baseline to Month 6 in 8-Point SMPG Profile Per Time Point
8-point SMPG profiles were measured for following 8 time points at Baseline and Month 6: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
Time frame: Baseline to Month 6
Percentage of Participants With at Least One Hypoglycemic Events (Any Hypoglycemia, Severe Hypoglycemia, Documented Symptomatic, Probable Symptomatic, Asymptomatic Hypoglycemia, Pseudo-hypoglycemia and Severe and/or Confirmed Hypoglycemia) at Month 12
Severe hypoglycemia: an event in which the child/adolescent having altered mental status and cannot assist in their care, is semiconscious or unconscious, or in coma ± convulsions and may require parenteral therapy (glucagon or glucose). Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (3.9 mmol/L). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=70 mg/dL. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration \<=70 mg/dL. Pseudo-hypoglycemia:an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>70 mg/dL.
Time frame: Month 12
Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12
Hyperglycemia with ketosis was defined as SMPG \>=252 mg/dL (14 mmol/L) with accompanying self-measured blood ketones \>=1.5 mmol/L.
Time frame: Month 12
The study was conducted at 105 centers in 24 countries. A total of 616 participants were screened between 14 April 2016 and 31 October 2017, of which 153 were screen failures. Screen failures were mainly due to glycated hemoglobin (HbA1c) level outside of defined ranges per eligibility criteria.
| Milestone | HOE901-U300 | Lantus |
|---|---|---|
| Started | 233 | 230 |
| Treated | 233 | 228 |
| Completed | 217 | 207 |
| Not completed | 16 | 23 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Poor compliance to protocol | 7 | 7 |
| Withdrew: Randomized and not treated | 0 | 2 |
| Withdrew: Other, not specified above | 5 | 11 |
Change in HbA1c was calculated by subtracting baseline value from Month 6 value. Adjusted least-square (LS) means and standard errors (SE) were obtained using analysis of covariance (ANCOVA) after multiple imputations of missing data using post-baseline HbA1c data available on the main 6-month randomized period.
| Percentage of HbA1c | HOE901-U300 | Lantus |
|---|---|---|
| Change From Baseline in HbA1c to Month 6 | -0.399 ± 0.063 | -0.402 ± 0.064 |
Change in FPG was calculated by subtracting baseline value from Month 6 value. Adjusted LS means and SE were obtained using ANCOVA after multiple imputation to address missing data in the main 6 month randomized period.
| millimole per liter (mmol/L) | HOE901-U300 | Lantus |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) to Month 6 | -0.563 ± 0.372 | -0.549 ± 0.372 |
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c Values of <7.5% at Month 6 | 26.18 | 23.48 |
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period | 4.29 | 4.78 |
Participants without any available FPG assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) at Month 6 | 27.47 | 26.52 |
Participants without any available HbA1c assessment at month 6 and/or with a premature study discontinuation during the main 6-month randomized period were considered as a failure (non-responders) in the analysis. Analysis was performed using Cochran-Mantel-Haenszel (CMH) method with randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With FPG of <=130 mg/dL (7.2 mmol/L) Without Any Episode of Severe and/or Documented (SMPG <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period | 9.44 | 7.39 |
8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%), randomization strata of age at screening (\<12 years, \>=12 years) and the baseline 24-hour average 8-point profile SMPG.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change From Baseline in 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles to Month 6 | 0.139 ± 0.249 | -0.266 ± 0.250 |
8-point SMPG profiles were measured at the following 8 points: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Variability was assessed by the coefficient of variation (standard deviation divided by mean) calculated over the 8-point SMPG. Analysis was performed using a ANCOVA model including the fixed categorical effects of treatment group, randomization strata of screening HbA1c (\<8.5%; \>=8.5%) and randomization strata of age at screening (\<12 years, \>=12 years).
| percentage of mean variability | HOE901-U300 | Lantus |
|---|---|---|
| Change From Baseline in Variability of 24-Hour Mean Plasma Glucose Based on 8-point SMPG Profiles at Month 6 | 1.469 ± 1.409 | 0.789 ± 1.415 |
8-point SMPG profiles were measured for following 8 time points at Baseline and Month 6: between 01:00 and 04:00 (clock time) at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Between 01:00 and 04:00 at night | 0.84 ± 6.94 | -0.60 ± 7.08 |
| Pre-breakfast | -0.41 ± 5.48 | -1.71 ± 6.56 |
| 2 hours after breakfast | -0.26 ± 7.18 | -0.62 ± 6.78 |
| Pre-lunch | 0.43 ± 6.99 | 1.11 ± 6.85 |
| 2 hours after lunch | 0.49 ± 7.64 | -0.55 ± 7.20 |
| Pre-dinner | 0.29 ± 8.05 | -0.02 ± 6.78 |
| 2 hours after dinner | 0.51 ± 8.53 | 0.60 ± 6.86 |
| Bedtime | 0.86 ± 7.60 | -0.60 ± 7.00 |
Severe hypoglycemia: an event in which the child/adolescent having altered mental status and cannot assist in their care, is semiconscious or unconscious, or in coma ± convulsions and may require parenteral therapy (glucagon or glucose). Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (3.9 mmol/L). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=70 mg/dL. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration \<=70 mg/dL. Pseudo-hypoglycemia:an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>70 mg/dL.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Any hypoglycemia | 99.1 | 98.7 |
| Severe Hypoglycemia | 8.6 | 11.0 |
| Documented Symptomatic Hypoglycemia | 94.8 | 93.9 |
| Probable Symptomatic Hypoglycemia | 10.3 | 13.6 |
| Asymptomatic Hypoglycemia | 88.4 | 89.5 |
| Pseudo-hypoglycemia | 15.9 | 14.5 |
| Severe and/or documented hypoglycemia | 99.1 | 98.2 |
Hyperglycemia with ketosis was defined as SMPG \>=252 mg/dL (14 mmol/L) with accompanying self-measured blood ketones \>=1.5 mmol/L.
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With Any Hyperglycemia With Ketosis at Month 12 | 9.9 | 13.6 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form until the end of the study (Week 58) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 | 1/233 (0.4%) | 35/233 (15%) | 105/233 (45.1%) |
| Lantus | 0/228 (0%) | 31/228 (13.6%) | 118/228 (51.8%) |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Hypoglycaemic SeizureNervous system disorders | 8/233 | 10/228 |
| Hypoglycaemic UnconsciousnessNervous system disorders | 6/233 | 10/228 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 5/233 | 6/228 |
| Alanine Aminotransferase IncreasedInvestigations | 3/233 | 1/228 |
| AppendicitisInfections and infestations | 1/233 | 2/228 |
| Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders | 2/233 | 2/228 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/233 | 0/228 |
| Adrenal InsufficiencyEndocrine disorders | 0/233 | 1/228 |
| GastroenteritisInfections and infestations | 1/233 | 1/228 |
| Meningococcal InfectionInfections and infestations | 0/233 | 1/228 |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| NasopharyngitisInfections and infestations | 37/233 | 39/228 |
| KetosisMetabolism and nutrition disorders | 19/233 | 30/228 |
| PharyngitisInfections and infestations | 14/233 | 22/228 |
| Upper Respiratory Tract InfectionInfections and infestations | 20/233 | 18/228 |
| InfluenzaInfections and infestations | 14/233 | 19/228 |
| HeadacheNervous system disorders | 19/233 | 15/228 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 15/233 | 7/228 |
| VomitingGastrointestinal disorders | 14/233 | 9/228 |
| OverweightMetabolism and nutrition disorders | 2/233 | 13/228 |
| GastroenteritisInfections and infestations | 12/233 | 10/228 |
Analysis was performed on all randomized participants.
| Age, Continuous(Years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 12.9 ± 2.9 | 12.9 ± 2.9 | 12.9 ± 2.9 |
| Sex: Female, Male(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Female | 105 | 121 | 226 |
| Male | 128 | 109 | 237 |
| Race (NIH/OMB)(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 6 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 6 | 14 |
| White | 211 | 211 | 422 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Body Mass Index (BMI)(BMI percentile) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 67.52 ± 26.62 | 69.13 ± 26.64 | 68.32 ± 26.61 |
| Hemoglobin A1C (HbA1C)(percentage of A1C) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 8.65 ± 0.88 | 8.61 ± 0.87 | 8.63 ± 0.88 |
Showing the first 100 of 107 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Apr 2016 to primary completion in May 2018, 25 months.
Results were first posted in Jun 2019, 1 year after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 25 months is above that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine